{'fraction_non_alphanumeric': 0.032362459546925564, 'fraction_numerical': 0.0, 'mean_word_length': 4.948717948717949, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Contribution of flow cytometry in the prognostic evaluation of non-small-cell lung cancers. Review of the literature].

The flow-cytometry (FCM) is a method of quickly determining the desoxyribonucleic acid (DNA) content of tumoral cells. This provides us with two results: the DNA-ploidy which characterizes quantitatively the DNA, and the percentage of cells in DNA synthesis phase (%S). The contribution of FCM in evaluation of the prognosis of non-small cell lung cancer remains disputable. The absence of standardization between laboratories makes it difficult to compare the different studies to define the place of FCM analysis. However, for epidermoid carcinomas, the most actively studied, a DNA diploidy and a weak %S have a favourable impact on survival. No conclusion can be drawn from the studies on adenocarcinomas. Large cell carcinomas have never been studied in an isolated manner, due to the lack of numbers.